David Benshoof Klein is CEO and Co-founder of Click Therapeutics, a leading innovator in the development of prescription digital therapeutics. He is also guest faculty at the Biotechnology Program at Columbia University, NYU’s Stern School of Business, and the Columbia Business School. He was Managing Director at Opus Point Partners, which created, financed, and operated more than 10 science companies, and Senior Consultant at Pfizer, and a strategic advisor for several publicly traded and privately held life science companies.
To identify true growth opportunities, investors must consider how companies are using AI to revolutionize the treatment journey. Some companies are doing just that via Software as a Medical Device (SaMD), particularly by developing prescription digital therapeutics (PDTs).
The challenge of introducing a novel therapy is nothing new. It has been done again and again, but always from a foundation of compelling evidence…gathered through a rigorous scientific approach that demonstrates quality, safety, efficacy, and a favorable balance of benefits and risks.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.